Journal
JOURNAL OF PATHOLOGY
Volume 224, Issue 4, Pages 461-472Publisher
WILEY
DOI: 10.1002/path.2870
Keywords
bacteria; intestinal fibrosis; experimental colitis; transforming growth factor beta 1; transforming growth factor beta receptor 1; smad 2; smad 3; tissue inhibitor of metalloproteinase-1; matrix metalloproteinases
Funding
- Science Foundation of Ireland (SFI) [RFP/BMT2781]
Ask authors/readers for more resources
Transforming growth factor beta (TGF-beta) is known to play a key role in intestinal fibrosis; however, the underlying mechanisms are not well understood. TGF-beta signal transduction is through TGF-beta receptors, including the TGF-beta type 1 receptor. Most cell types contain a TGF-beta type 1 receptor form known as activin receptor-like kinase 5 (ALK5), which propagates the signal to the nucleus through the phosphorylation of Smad2 and Smad3 proteins. Therefore, we assessed the effect of the disruption of TGF-beta/ALK5/Smad signalling by an ALK5 inhibitor (SD-208) in two experimental animal models of intestinal fibrosis: anaerobic bacteria-and trinitrobenzensulphonic acid-induced colitis. In addition, isolated myofibroblasts were pretreated with SD-208 and exposed to recombinant TGF-beta 1. Finally, myofibroblasts were transfected with ALK5, Smad2, and Smad3-specific siRNA. Up-regulation of ALK5 and TIMP-1, phosphorylation of Smad2 and Smad3 proteins, and increased intestinal wall collagen deposition were found in both experimental animal models. These effects were decreased by SD-208. TGF-beta 1 treatment also induced phosphorylation of Smad2 and Smad3 and up-regulation of ALK5 protein, TIMP-1, and alpha 2 type 1 collagen gene expression in isolated myofibroblasts. Again these effects were inhibited by SD-208. Also, ALK5, Smad2, and Smad3 siRNA abolished the induction of TIMP-1 and alpha 2 type 1 collagen. Our findings provide evidence that the TGF-beta/ALK5/Smad pathway participates in the pathogenesis of experimental intestinal fibrosis. These data show promise for the development of an effective therapeutic intervention in this condition. Copyright (C) 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available